1 withdrawn. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Withdrawn 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow enoblituzumab: new trials by email Literature Review of enoblituzumab trials Research Report on enoblituzumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck enoblituzumab, MGA012, MGD013 - Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck | Phase 2 / Phase 3 | Withdrawn | MacroGenics | 2019-10-01 | 2022-02-08 |
Head and Neck Neoplasms (1) · Laryngeal Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
MacroGenics (1)